trending Market Intelligence /marketintelligence/en/news-insights/trending/10z6mwm3rkwhvoupficr8g2 content esgSubNav
In This List

IntelGenx drops plans to buy pharmaceutical consulting firm

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


IntelGenx drops plans to buy pharmaceutical consulting firm

IntelGenx Technologies Corp. said March 27 that it is no longer looking to raise $10 million to fund the acquisition of a pharmaceutical consulting firm.

The company canceled its placement due to market conditions. The Canadian drug delivery company's acquisition of LaboVal Inc. was dependent on the financing.